The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not really. Have a read of the RNS. they battered a load of stop losses, Hoovered up the shares and now selling them again. Not a single sell today, all buys on level 2. I don't expect it to be this low in a few sessions.
Was there a particular reason for the drop?
Substantial buying going through on level 2 now. Someone been given the nod again.
going up after yesterdays silly drop
would hope this to go 25% up......at least...but no interest.....yet!
just looks like some chunky sales (7) compared to buying (2) today..still higher SP than your 19th Dec price/post
what is going on here...Is it only the adjusted revenue process or something else at play here?
well they did rise a bit after last post but guess the market didn't like the adjusted revenue process, which is better to do in the long run
glad I waited!!
looks like it..
buy in again?
The neuroscience technology company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, today announced its voice biomarker and AI platform, NeuroVocalixâ, for use in clinical trials.
Having filed patents and announced the start of the technology programme last year, the Company has now confirmed its first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels.
There is a blog post on Cambridge Cognition available here: hTTps://www.sharesoc.org/blog/company-news/abcam-agm-cambridge-cognition-ultra-electronics-wey-education-idox/
There is a detailed report on our recent London seminar where Cognition recently presented which can be found in our members area here: hTTps://www.sharesoc.org/members-area/ To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps://www.sharesoc.org/membership/ Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://www.sharesoc.org/contact-us/ For our future seminars you may want to see here: hTTps://www.sharesoc.org/events/
Cambridge Cognition Holdings plc (Cambridge, UK - LSE: COG, 'Company'), the neuroscience digital health company, is pleased to announce it has been awarded £0.3m of R&D funding by the UK's innovation agency, Innovate UK, to develop a novel digital health system which will elicit and automatically analyse pain-related signals in human speech. This pioneering new project will see Cambridge Cognition develop a digital health system for objective measurement of pain based on signals in a person's voice. It follows the Company successfully demonstrating the feasibility of automated verbal cognitive assessments on consumer voice platforms at the Alzheimer's Association International Conference in July 2017 as detailed in the Company announcement made on 7 June 2017.
You won't get "chat" on here mate if the company have no debt to forward-sell to PIs at 2x tomorrow's borrowing price ...
had a 140-170p target range from 77p here in the 25th March chart update notes on my site - nice to see her make it ;)
our AI/ASR tech RNS the other week didn't even generate any chatter on here..
Not much chat hear - would have thought more if you are sat on 100%+ More to go? Will this be taken out??
doing well since I found this at 70p... didnt buy of course! New contract rumours? Not in but interesting...
Tipped by ST in IC mag online. Target 130p
Can't find news on this. Any idea why the spectacular price rise over the last few days?
thinking about buying into here great results defo in the right market too :)
should hopefully see a nice little rise of the back of this RNS. No rise in the sp pre RNS to underpin current price so can't see a sell off on the release of good news!!
nice results! The neuroscience digital health company Cambridge Cognition Holdings plc, (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health, today announces its audited preliminary results for the year ended 31 December 2016. Financial Highlights · Total revenues increased by 37% to £6.88m (2015: £5.04m) · Maiden profit for the year of £0.22m (2015: loss of £0.78m*) · Earnings per share of 1.4p (2015: loss of 4.6p*) · Operational cashflow of £0.47m (2015: outflow of £0.71m) · Net cash balances at 31 December 2016 of £2.38m (31 December 2015: £0.76m) · Successful equity placing of £1.25m (£1.14m net proceeds) in April 2016 * Loss in 2015 includes impact of £0.21m one-off exceptional item. There are no exceptional items in 2016. Operational Highlights · Portfolio of products and services expanded to meet needs of wider psychiatric and neurological disease areas · New products to meet the needs of new healthcare economics o More efficient R&D (Recruit product) o Demonstration of treatment benefits (wearable product) · Software and services revenues up 35% to £6.19m (2015: £4.59m) · First contracts won for new wearables and Recruit products · Higher number of new product launches in the year despite lower R&D spend (£0.89m in 2016 compared with £1.30m in 2015) · Commitment made at placing to invest in sales team met and already demonstrating benefits · FDA clearance for CANTAB Mobile enables marketing in the US